AgingResearch.NewsJoin free

Phase 1/2Active, not recruitingAge-related condition

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy (ArMaDa)

A Phase 1/2 Study to Assess the Safety And Efficacy Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

Sponsor
Ocugen (Industry)
Enrollment
60 enrolled
Conditions
Geographic Atrophy
Interventions
OCU410
Ages
adults, older adults
Registry
NCT06018558

Full record on ClinicalTrials.gov

From the registry

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 60 subjects.

Primary outcomes

  • Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))
  • Change in anatomy of ocular structures using Slit Lamp Biomicroscopy
  • Change in anatomy of ocular structures using Indirect ophthalmoscopy
  • Change from baseline in BCVA (Best Corrected Visual Acuity)

History

  1. Study completion expected

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered